Vandoeuvre lès Nancy
Service d’hématologie clinique,
Service de cancérologie, hématologie, thérapie cellulaire,
CHRU de Tours,
Service d’immunologie clinique,
Service des maladies du sang,
Significant progress has been made in the treatment of Multiple Myeloma and clinicians now have access to a broad variety of therapeutic agents. While first-line treatments are currently well-defined in France, the therapeutic options after first relapse are numerous and non-consensual. In order to propose a clear decision algorithm applicable to most first-relapse situations, a group of French haematology experts was formed. The answers provided are based on an exhaustive analysis of the literature, but also on their day-to-day experience and on the indications of the various molecules for which French marketing authorisations (MAs) have been granted. The purpose of this practical guide on the treatment of first-relapse multiple myeloma is to assist clinicians in their choice of second-line treatment and proposes two treatment algorithms (i) in subjects having undergone intensive first-line treatment and (ii) in subjects having received alkylating agent and corticosteroid (Melphalan-Prednisone) based first-line chemotherapy.